Orion pharmaceutical research earmarked for EIB money

Published: 14-Aug-2009
Research & Development

EIB to lend Orion Euro 75m to help pharmaceutical research and development work


The European Investment Bank (EIB) is planning to lend Finland's Orion Euro 75m to help it stage pharmaceutical research and development work from this year to 2012.

Part of a â"šÂ¬300m programme, the work would be carried out within Orion's existing r&d facilities, laboratories, pilot plants and clinical centres.

  • Companies:
  • Orion Group
See more

You may also like

Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Read more
Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)

Trending Articles

  1. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  2. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  3. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  4. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  5. Macomics unveils Anti-Pan-LILRB monoclonal antibody programme Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)
Research & Development

Orion and MSD announce two Phase III trials to evaluate ODM-208/MK5684 in patients with metastatic castration-resistant prostate cancer

OMAHA1 and OMAHA2a are the first Phase III trials to be initiated for ODM-208/MK5684
Research & Development

Orion and MSD announce global collaboration to develop and commercialise ODM-208

Agreement strengthens and complements MSD’s oncology pipeline
Drug Delivery

Nanoform and Orion collaborate on next-generation drug development

This collaboration will utilise Nanoform’s proprietary CESS technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development
Research & Development

In the pursuit of new medicines for oncological diseases

The Wisconsin Technology Innovation Initiative (Wi2) and Orion Corporation have announced a new strategic collaboration
Research & Development

Endo and Orion agree collaboration deal

Will bring forward eight drug candidates and share development costs
Drug Delivery

DelSiTech in research collaboration with Orion

Sign agreement that will enable Orion to apply DelSiTech proprietary drug delivery technology
Subscribe now